Current Research Status of Metronomic Chemotherapy in Combination Treatment of Breast Cancer

Overview

Journal Oncol Res Treat

Specialty Oncology

Date 2022 Aug 21

PMID 35988534

Authors

Jiaxuan Liu

Maiyue He

Zijing Wang

Qiao Li

Binghe Xu

Affiliations

Soon will be listed here.

Abstract

Background: Metronomic chemotherapy (MCT), termed sustained low-dose administration with minimal toxicity, is a new modality of conventional chemotherapy, a verified therapy alternative, and has acquired significant recognition and interest in oncology. Numerous clinical trials of MCT in combination with other treatments, including targeted therapies, biologics, and endocrine therapy, are in progress to obtain better results.

Summary: We comprehensively described the clinical benefits of MCT in combination with other treatments in different molecular subtypes of breast cancer and assessed the feasibility of its adoption in varying phases of treatment. Due to the promising preclinical and clinical investigations, it is expected that MCT in combination with other treatments will enhance the advantages of this strategy and apply it to clinical practice.

Key Message: MCT, in combination with other therapeutic interventions, will fully exploit the benefits of this strategy, ushering in a new paradigm in oncology treatment and driving the transformation of cancer into a more manageable chronic disease using newly developed treatment approaches.

Citing Articles

Efficacy and Safety of Metronomic Capecitabine in Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.

Gupta N, Verma N, Patel B J Gastrointest Cancer. 2024; 55(4):1485-1497.

PMID: 39160369 DOI: 10.1007/s12029-024-01103-w.

The inherent fragility of collective proliferative control.

Caldwell M, Lander A bioRxiv. 2024; .

PMID: 38328163 PMC: 10849578. DOI: 10.1101/2024.01.23.576783.

Metronomic chemotherapy and drug repurposing: A paradigm shift in oncology.

Jan N, Sofi S, Qayoom H, Shabir A, Haq B, Macha M Heliyon. 2024; 10(3):e24670.

PMID: 38314272 PMC: 10837507. DOI: 10.1016/j.heliyon.2024.e24670.

Induced Vascular Normalization-Can One Force Tumors to Surrender to a Better Microenvironment?.

Sun X, Nosrati Z, Ko J, Lee C, Bennewith K, Bally M Pharmaceutics. 2023; 15(8).

PMID: 37631236 PMC: 10458586. DOI: 10.3390/pharmaceutics15082022.

A phase II study of a doublet metronomic chemotherapy regimen consisting of oral vinorelbine and capecitabine in Chinese women with HER2-negative metastatic breast cancer.

Chai Y, Liu J, Jiang M, He M, Wang Z, Ma F Thorac Cancer. 2023; 14(23):2259-2268.

PMID: 37402471 PMC: 10423658. DOI: 10.1111/1759-7714.15011.

References

Aurilio G, Munzone E, Botteri E, Sciandivasci A, Adamoli L, Minchella I . Oral metronomic cyclophosphamide and methotrexate plus fulvestrant in advanced breast cancer patients: a mono-institutional case-cohort report. Breast J. 2012; 18(5):470-4. DOI: 10.1111/j.1524-4741.2012.01278.x. View

du Manoir J, Francia G, Man S, Mossoba M, Medin J, Viloria-Petit A . Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts. Clin Cancer Res. 2006; 12(3 Pt 1):904-16. DOI: 10.1158/1078-0432.CCR-05-1109. View

Hanahan D, Bergers G, Bergsland E . Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest. 2000; 105(8):1045-7. PMC: 300842. DOI: 10.1172/JCI9872. View

Xu B, Yan M, Ma F, Hu X, Feng J, Ouyang Q . Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021; 22(3):351-360. DOI: 10.1016/S1470-2045(20)30702-6. View

Gille J, Spieth K, Kaufmann R . Metronomic low-dose chemotherapy as antiangiogenic therapeutic strategy for cancer. J Dtsch Dermatol Ges. 2005; 3(1):26-32. DOI: 10.1046/j.1439-0353.2005.04048.x. View

Ueno T, Masuda N, Kamigaki S, Morimoto T, Saji S, Imoto S . Differential Involvement of Autophagy and Apoptosis in Response to Chemoendocrine and Endocrine Therapy in Breast Cancer: JBCRG-07TR. Int J Mol Sci. 2019; 20(4). PMC: 6412499. DOI: 10.3390/ijms20040984. View

Dellapasqua S, Bertolini F, Bagnardi V, Campagnoli E, Scarano E, Torrisi R . Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol. 2008; 26(30):4899-905. DOI: 10.1200/JCO.2008.17.4789. View

Petry V, Gagliato D, Leal A, Arai R, Longo E, Andrade F . Metronomic chemotherapy in the neoadjuvant setting: results of two parallel feasibility trials (TraQme and TAME) in patients with HER2+ and HER2- locally advanced breast cancer. Braz J Med Biol Res. 2015; 48(5):479-85. PMC: 4445673. DOI: 10.1590/1414-431X20144354. View

Garcia-Teijido P, Cabal M, Pelaez Fernandez I, Perez Y . Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting. Clin Med Insights Oncol. 2016; 10(Suppl 1):31-9. PMC: 4822722. DOI: 10.4137/CMO.S34540. View

10.

Shurin G, Tourkova I, Kaneno R, Shurin M . Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism. J Immunol. 2009; 183(1):137-44. PMC: 4005417. DOI: 10.4049/jimmunol.0900734. View

11.

Nakasone E, Askautrud H, Kees T, Park J, Plaks V, Ewald A . Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. Cancer Cell. 2012; 21(4):488-503. PMC: 3332002. DOI: 10.1016/j.ccr.2012.02.017. View

12.

Bazzola L, Foroni C, Andreis D, Zanoni V, Cappelletti M, Allevi G . Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer. Br J Cancer. 2014; 112(1):52-60. PMC: 4453610. DOI: 10.1038/bjc.2014.563. View

13.

Chue B, La Course B . Case report of long-term survival with metastatic triple-negative breast carcinoma: Treatment possibilities for metastatic disease. Medicine (Baltimore). 2019; 98(16):e15302. PMC: 6494386. DOI: 10.1097/MD.0000000000015302. View

14.

Chue B, La Course B . Can we cure stage IV triple-negative breast carcinoma?: Another case report of long-term survival (7 years). Medicine (Baltimore). 2019; 98(38):e17251. PMC: 6756617. DOI: 10.1097/MD.0000000000017251. View

15.

Tanaka H, Matsushima H, Nishibu A, Clausen B, Takashima A . Dual therapeutic efficacy of vinblastine as a unique chemotherapeutic agent capable of inducing dendritic cell maturation. Cancer Res. 2009; 69(17):6987-94. PMC: 2737094. DOI: 10.1158/0008-5472.CAN-09-1106. View

16.

Kummar S, Wade J, Oza A, Sullivan D, Chen A, Gandara D . Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer. Invest New Drugs. 2016; 34(3):355-63. PMC: 4860030. DOI: 10.1007/s10637-016-0335-x. View

17.

Perroud H, Alasino C, Rico M, Queralt F, Pezzotto S, Rozados V . Quality of life in patients with metastatic breast cancer treated with metronomic chemotherapy. Future Oncol. 2016; 12(10):1233-42. PMC: 4976839. DOI: 10.2217/fon-2016-0075. View

18.

Cimino-Mathews A, Foote J, Emens L . Immune targeting in breast cancer. Oncology (Williston Park). 2015; 29(5):375-85. View

19.

Cazzaniga M, Torri V, Riva F, Porcu L, Cicchiello F, Capici S . Efficacy and safety of vinorelbine-capecitabine oral metronomic combination in elderly metastatic breast cancer patients: VICTOR-1 study. Tumori. 2016; 103(1):e4-e8. DOI: 10.5301/tj.5000543. View

20.

Orlando L, Cardillo A, Ghisini R, Rocca A, Balduzzi A, Torrisi R . Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer. BMC Cancer. 2006; 6:225. PMC: 1579231. DOI: 10.1186/1471-2407-6-225. View